VivoSeq
Oncology

Solitary Fibrous Tumor

6

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Solitary Fibrous Tumor is an early-stage landscape with 6 programs across 5 companies. The most active players are Eisai, Prism Pharmaceuticals, Bayer.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eisai logo

Eisai

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2H

HRYZ Biotech Co.

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 26

Eribulin

Eisai

Axitinib

Prism Pharmaceuticals

Trabectedin

Apotex Inc.

Dacarbazine

Bayer

Pazopanib

Novartis

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Completed4 · 100%

Clinical Trials

Trial Activity

Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor
Completed·IItalian Sarcoma Group·Phase 2·NCT03023124·23 enrolled
Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02261207·17 enrolled
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 2·NCT02066285·96 enrolled
Eribulin in Advanced Solitary Fibrous Tumor
Completed·IItalian Sarcoma Group·Phase 2·NCT03840772·16 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)